News >

Early Chemo Linked to Improved PFS in High-Volume Metastatic Prostate Cancer

Jason Harris
Published: Thursday, Aug 10, 2017

Prostate Cancer
Patients with high-volume, castration-naïve metastatic prostate cancer may have superior progression-free survival (PFS) outcomes when treated with early docetaxel, according to findings published online in the European Journal of Cancer.

, the difference between Q-TWiST significantly favored ADT/docetaxel at all values of uprog lower than 0.4.
Marino P, Sfumato P, Joly F, et al. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial. Eur J Cancer. 2017;84:27-33. doi:10.1016/j.ejca.2017.07.008.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Publication Bottom Border
Border Publication
x